Pancreatic Cancer Research

ResearcherIcahn School of Medicine at Mount SinaiActive in the last 2 years

Marc Zins

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5694-1238; OpenAlex author ID A5085336573, A5158664913. Sources: ClinicalTrials.gov.

Their work

Papers
18 (first author 0, last author 5)
Trials
2 (principal investigator on 2)
Grants
0
Labs led
1
Collaborators
56
Papers, trials and grants by year

2015: 2 papers · 2016: none · 2017: none · 2018: 2 papers · 2019: 1 paper, 1 trial · 2020: 3 papers · 2021: 1 paper · 2022: 2 papers, 1 trial · 2023: 3 papers · 2024: 1 paper · 2025: 2 papers · 2026: 1 paper

Papers 18

  1. Restaging the primary tumor in localized pancreatic ductal adenocarcinoma after systemic therapy: a scoping review of the role of CT, FDG-PET, and CA19-9. Co-author DOI 10.1007/s00330-026-12954-1↗
  2. A risk score system including CT features for predicting early recurrence of resectable pancreatic ductal adenocarcinoma after radical resection: a dual-center… Co-author DOI 10.1007/s00330-025-11632-y↗
  3. Factors Associated With Aborted Whipple Procedures for Periampullary Carcinoma: A Multicenter Case-Control Study by the SAR Pancreatic Ductal Adenocarcinoma Di… Co-author DOI 10.2214/ajr.24.32160↗
  4. Editorial Comment: CT Surveillance for Local Recurrence After Pancreatic Cancer Resection-Focus on Perivascular Soft Tissue in the Surgical Bed. Co-author DOI 10.2214/ajr.24.31999↗
  5. Postoperative surveillance of pancreatic ductal adenocarcinoma (PDAC) recurrence: practice pattern on standardized imaging and reporting from the society of ab… Co-author DOI 10.1007/s00261-022-03693-0↗
  6. Determination of "borderline resectable" pancreatic cancer - A global assessment of 30 shades of grey. Last author DOI 10.1016/j.hpb.2023.07.883↗
  7. Invited Commentary: Failures in Imaging Diagnosis of Pancreatic Cancer: Can We Avoid Them and How? Co-author DOI 10.1148/rg.230217↗
  8. Fractal analysis improves tumour size measurement on computed tomography in pancreatic ductal adenocarcinoma: comparison with gross pathology and multi-paramet… Last author DOI 10.1007/s00330-022-08631-8↗
  9. Imaging Assessment of Pancreatic Cancer Resectability After Neoadjuvant Therapy: AJR Expert Panel Narrative Review. Last author DOI 10.2214/ajr.21.26931↗
  10. European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Pancreatic Cancer. Co-author DOI 10.1016/j.ctrv.2021.102208↗
  11. White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part I, AJCC … Co-author DOI 10.1007/s00261-019-02289-5↗
  12. White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part II, upda… Co-author DOI 10.1007/s00261-019-02290-y↗
  13. Therapeutic response assessment in pancreatic ductal adenocarcinoma: society of abdominal radiology review paper on the role of morphological and functional im… Co-author DOI 10.1007/s00261-020-02723-z↗
  14. Initial Diagnosis and Staging of Pancreatic Cancer Including Main Differentials. Last author DOI 10.1053/j.sult.2019.08.001↗
  15. Staging of pancreatic cancer: resectable, borderline resectable, and unresectable disease. Co-author DOI 10.1007/s00261-017-1410-2↗
  16. Pancreatic Adenocarcinoma Staging in the Era of Preoperative Chemotherapy and Radiation Therapy. Co-author DOI 10.1148/radiol.2018171670↗
  17. Pancreatic adenocarcinoma: MRI conspicuity and pathologic correlations. Last author DOI 10.1007/s00261-014-0196-8↗
  18. [Conventional imaging of pancreatic cancer]. Co-author PMID 26016200↗

Trials 2

  1. Neoadjuvant Treatment of Resectable or Locally Advanced Borderline Pancreatic Adenocarcinoma: Reproducibility of Tumor Measurement in CT VS MRI Principal investigator NCT05511116↗
  2. Evaluation of the FOCUS Diffusion's Added Clinical Value Compared to Conventional MRI Principal investigator NCT03961646↗

Closest collaborators

The 25 strongest of 56 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Erik V. Soloff · 7 shared papers, 2018–2025 · strength 0.87
  2. Zhen J. Wang · 5 shared papers, 2020–2025 · strength 0.58
  3. Avinash R. Kambadakone · 5 shared papers, 2020–2025 · strength 0.58
  4. Eric Peter Tamm · 5 shared papers, 2018–2023 · strength 0.52
  5. Atif Zaheer · 4 shared papers, 2018–2025 · strength 0.50
  6. Elizabeth M. Hecht · 4 shared papers, 2020–2025 · strength 0.48
  7. Priya Bhosale · 4 shared papers, 2020–2023 · strength 0.41
  8. Richard Kinh Gian · 3 shared papers, 2020–2025 · strength 0.39
  9. Naveen M. Kulkarni · 3 shared papers, 2020–2023 · strength 0.31
  10. Olga Rachel Brook · 3 shared papers, 2020–2023 · strength 0.31
  11. Lorenzo Mannelli · 3 shared papers, 2020–2023 · strength 0.31
  12. Parag P. Tolat · 3 shared papers, 2020–2023 · strength 0.31
  13. Elliot K. Fishman · 2 shared papers, 2022–2023 · strength 0.31
  14. Jin Peng He · 2 shared papers, 2023–2025 · strength 0.29
  15. Samuel Joseph Galgano · 2 shared papers, 2023–2025 · strength 0.29
  16. Lyndon Luk · 2 shared papers, 2023–2025 · strength 0.29
  17. Candice W. Bolan · 2 shared papers, 2023–2025 · strength 0.29
  18. Linda Chi Hang Chu · 2 shared papers, 2023–2025 · strength 0.29
  19. Inez M. Verpalen · 1 shared paper, 2026 · strength 0.29
  20. A. M. Lamoré · 1 shared paper, 2026 · strength 0.29
  21. Marc G. Besselink · 1 shared paper, 2026 · strength 0.29
  22. Axel Dallongeville · 2 shared papers, 2019–2022 · strength 0.29
  23. Zixing Huang · 1 shared paper, 2025 · strength 0.25
  24. Yan Deng · 1 shared paper, 2025 · strength 0.25
  25. Dan Cao · 1 shared paper, 2025 · strength 0.25

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.